Clinical trial

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCT00100165

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-01-01

PhasePHASE2

Study timeline

Study start (unknown)2005-01-01Date precision: month

Registry last updated2020-01-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

3-(2,4 dimethoxybenzylidene anabaseine) 150 mgDRUG

3-(2,4 dimethoxybenzylidene anabaseine) 75 mgDRUG

Sponsors & collaborators

University of Colorado, Denverlead sponsor

VA Office of Research and Developmentcollaborator

Mapped research locations

DenverColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00100165 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.